Drug Discovery Stories, Volume 2
eBook - ePub

Drug Discovery Stories, Volume 2

  1. 725 pages
  2. English
  3. ePUB (mobile friendly)
  4. Available on iOS & Android
eBook - ePub

Drug Discovery Stories, Volume 2

About this book

Drug Discovery Stories, Volume Two showcases the discovery journeys of recent blockbuster drugs approved between 2023 and 2024, along with promising drug candidates. This book delves into structural biology, biological functions of targets, hit compound identification, hit-to-lead optimization, binding modes, key biological and pharmacokinetic data, and clinical results. It also covers other candidate compounds against the same targets and includes additional content based on the authors' choices. The series addresses the rapid evolution in drug discovery and development, appealing to those in chemical biology, synthetic chemistry, and pharmacology.By highlighting interdisciplinary collaboration, the authors plan to release updated editions every few years to ensure the content reflects the latest achievements and breakthroughs in the field. - Analyzes the drug discovery stories of different blockbuster drugs - Covers key aspects related to the drug development of the drugs - Includes the newly approved drugs

Trusted by 375,005 students

Access to over 1.5 million titles for a fair monthly price.

Study more efficiently using our study tools.

Information

Publisher
Elsevier
Year
2025
eBook ISBN
9780443338861
Topic
Physical Sciences
Subtopic
Pharmacology

Table of contents

  1. Title of Book
  2. Cover image
  3. Title page
  4. Table of Contents
  5. Copyright
  6. List of contributors
  7. About the editors
  8. Foreword
  9. Preface
  10. Chapter 1 Piet De Somer (1917–85): a scientific career
  11. Chapter 2 Sculpting the future: harnessing artificial intelligence for revolutionary drug discovery
  12. Chapter 3 The role of early development as key success factor for drug discovery and development
  13. Chapter 4 Conception of antivirals: a historical perspective
  14. Chapter 5 Azvudine: a reverse transcriptase inhibitor for AIDS and COVID-19 treatment
  15. Chapter 6 Ensitrelvir: an oral noncovalent nonpeptidic SARS-CoV-2 main protease inhibitor with potent clinical effect
  16. Chapter 7 Leritrelvir (RAY1216): a novel α-ketoamide-based peptidomimetic inhibitor of SARS-CoV-2 main protease for COVID-19 treatment
  17. Chapter 8 Remdesivir: an early repurposed RNA-dependent RNA polymerase inhibitor for treating COVID-19
  18. Chapter 9 Cabotegravir as an HIV-1 integrase strand transfer inhibitor: from workbench to clinical development
  19. Chapter 10 Uncovering the main hepatitis B virus receptor, sodium taurocholate cotransporting polypeptide, and its sequel to promising clinical trials with bulevirtide
  20. Chapter 11 The journey of highly potent dengue virus inhibitor, JNJ-A07 and JNJ-1802 from lab to clinic
  21. Chapter 12 Benzoxaborole drugs in therapy: successful cases of Tavaborole and Crisaborole
  22. Chapter 13 Enmetazobactam: an extended-spectrum beta-lactamase inhibitor in countering antimicrobial resistance
  23. Chapter 14 Taniborbactam (VNRX-5133): a broad-spectrum serine- and metallo-β-lactamase inhibitor for carbapenem-resistant bacterial infections
  24. Chapter 15 Rezafungin: A β-(1,3)-D-glucan synthase inhibitor as antifungal drug derived from Echinocandin B0
  25. Chapter 16 Beyond bedaquiline: the new generation of mycobacterial adenosine triphosphate synthase inhibitors TBAJ-587, TBAJ-876, and WX-081 for the treatment of drug-resistant tuberculosis
  26. Chapter 17 Fexinidazole: a chink in the armor of human African trypanosomiasis
  27. Chapter 18 Chiglitazar/Carfloglitazar, a drug for the treatment of type 2 diabetes mellitus and more
  28. Chapter 19 Semaglutide: a glucagon-like peptide-1 receptor agonist and its therapeutic potential in type 2 diabetes and beyond
  29. Chapter 20 Danuglipron: pioneering oral glucagon-like peptide-1 receptor agonists paving the way forrevolutionizing diabetes treatment
  30. Chapter 21 Donepezil: cholinesterase inhibitor for the treatment of Alzheimer's disease
  31. Chapter 22 Roflumilast: a selective phosphodiesterase-4 inhibitor for the treatment of Alzheimer’s disease
  32. Chapter 23 Omaveloxolone: a nuclear factor erythroid 2-related factor 2 activator for Friedreich’s ataxia
  33. Chapter 24 Gepirone: a selective partial agonist of the 5-HT1A receptor in the treatment of depression
  34. Chapter 25 Olverembatinib: a potent Bcr-Abl third-generation inhibitor for the treatment of chronic myeloid leukemia
  35. Chapter 26 STX-478, RLY-2608, and LOXO-783: third-generation PIK3CA mutant-selective allosteric inhibitors
  36. Chapter 27 Repotrectinib (TPX-0005): a macrocyclic ALK/ROS1/TRK inhibitor for the treatment of nonsmall cell lung cancer
  37. Chapter 28 FRUZAQLA (fruquintinib): a selective oral inhibitor of VEGFR -1, -2, and -3 for treating adults with metastatic colorectal cancer
  38. Chapter 29 RNK-05047: a chaperone-mediated protein degrader that selectively targets BRD4 while recruiting the HSP90 chaperone
  39. Chapter 30 Belzutifan: a first-in-class oral HIF-2α inhibitor approved for patients with von Hippel-Lindau disease-associated renal cell carcinoma
  40. Chapter 31 JPH-203: a LAT1 inhibitor as a promising solution for advanced refractory biliary tract cancer
  41. Chapter 32 Fluzoparib: the first Chinese original poly(ADP-ribose)polymerase inhibitor for the treatment of BRCA1/2 mutated ovarian cancer
  42. Chapter 33 Idecabtagene vicleucel: the first BCMA-targeted CAR-T cell therapy for multiple myeloma
  43. Chapter 34 NX-5948: a Bruton’s tyrosine kinase degrader in Ph. Ia/Ib for patients with advanced B-cell malignancies
  44. Chapter 35 Fingolimod (Gilenya): a sphingosine-1-phosphate receptor modulator for the treatment of multiple sclerosis
  45. Chapter 36 Momelotinib: a new frontier as a JAK1 and JAK2 inhibitor in hematological disorders
  46. Chapter 37 Imetelstat: a first-in-class telomerase inhibitor for treating myelodysplastic syndromes
  47. Chapter 38 Zanubrutinib in liquid cancers a new horizon
  48. Chapter 39 Piflufolastat F-18, Illuccix, Posluma, Pluvicto, and beyond: the development of radiopharmaceuticals for prostate cancer theranostics
  49. Chapter 40 Daprodustat (GSK-1278863): a small molecule hypoxia inducible factor-prolyl hydroxylase inhibitor for anemia
  50. Chapter 41 FABHALTA (iptacopan): an innovative advancement in the treatment of paroxysmal nocturnal hemoglobinuria
  51. Chapter 42 Resmetirom: a first-in-class thyroid hormone receptor β agonist approved by FDA for patients with nonalcoholic steatohepatitis
  52. Chapter 43 Fezolinetant: the first FDA-approved neurokinin-3 receptor antagonist for treating moderate-to-severe vasomotor symptoms associated with menopause
  53. Chapter 44 Nerandomilast (BI 1015550): an efficient PDE4 inhibitor for the potential treatment of idiopathic pulmonary fibrosis
  54. Chapter 45 Vamorolone: a dissociative steroid for the treatment of Duchenne muscular dystrophy
  55. Chapter 46 Sotagliflozin: a dual SGLT1/2 inhibitor, for full range of heart failure
  56. Chapter 47 Drug development based on natural products of Euphorbia genus
  57. Index

Frequently asked questions

Yes, you can cancel anytime from the Subscription tab in your account settings on the Perlego website. Your subscription will stay active until the end of your current billing period. Learn how to cancel your subscription
No, books cannot be downloaded as external files, such as PDFs, for use outside of Perlego. However, you can download books within the Perlego app for offline reading on mobile or tablet. Learn how to download books offline
Perlego offers two plans: Essential and Complete
  • Essential is ideal for learners and professionals who enjoy exploring a wide range of subjects. Access the Essential Library with 800,000+ trusted titles and best-sellers across business, personal growth, and the humanities. Includes unlimited reading time and Standard Read Aloud voice.
  • Complete: Perfect for advanced learners and researchers needing full, unrestricted access. Unlock 1.5M+ books across hundreds of subjects, including academic and specialized titles. The Complete Plan also includes advanced features like Premium Read Aloud and Research Assistant.
Both plans are available with monthly, semester, or annual billing cycles.
We are an online textbook subscription service, where you can get access to an entire online library for less than the price of a single book per month. With over 1.5 million books across 990+ topics, we’ve got you covered! Learn about our mission
Look out for the read-aloud symbol on your next book to see if you can listen to it. The read-aloud tool reads text aloud for you, highlighting the text as it is being read. You can pause it, speed it up and slow it down. Learn more about Read Aloud
Yes! You can use the Perlego app on both iOS and Android devices to read anytime, anywhere — even offline. Perfect for commutes or when you’re on the go.
Please note we cannot support devices running on iOS 13 and Android 7 or earlier. Learn more about using the app
Yes, you can access Drug Discovery Stories, Volume 2 by Bin Yu,Peng Zhan in PDF and/or ePUB format, as well as other popular books in Physical Sciences & Pharmacology. We have over 1.5 million books available in our catalogue for you to explore.